Autologous Hematopoietic Stem Cell Transplant (aHSCT) is a Safe and Reasonable Treatment in Patients with Primary Systemic Amyloidosis (AL amyloidosis)
Year: 2013
Type: article
Abstract: There is no current standard of care for patients with newly diagnosed AL amyloidosis. Autologous HSCT is a potential option, but has been limited in its use due to increasd treatment-related mortality (TRM) (38% from one randomized study). Two large retrospective analyses showed improved overall survival (OS) (70% at 4 yrs and 47% at 5 yrs) of AL amyloid patients undergoing aHSCT compared to control (40% at 4 yrs) with TRM of 13%.
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W2148459333